Member Info for RiskIsReward

The genetic code of one in 500 people puts them at higher risk of losing their hearing if they take antibiotic gentamicin

I meant how much 6 machine are making now?
What is stopping in posting number from initial POC orders? it is surely bigger than zero?

The only one thing that can move this sp is sales and revenue.
Budd just need disclose the information which he already has:
How much are we making with 6 AIHL machines installed? expected revenue from this in next 12 to 15 months?
Initial order on POC, what is it worth?
The people here need to less bother about derampers on this BB and start asking Budd questions?Why does he need to hide them? does he not like sp to take off?

you need to read out NICE study..
Show me where in RNS it states Manchester are paying money for these installations? You con post this question in investor and let see if Budd answers it.

AIHL needs data from manchester trust and further studies to be widely accepted and rolled out.
I cant see any POC sales news landing soon.
As usual David Budd will go silent for next 3 months...

More than 100 million shares traded since last 8 days..
Highly volatile share, need some sales/revenues to get II's on board.

I dont think you would survive in any industry with such results.. very poor show from him.
Years of developemnt and investors money is poured into gutter. dumped HCV, PCR test and US DOD.
He is once agian dangling the carrot "Initial POC orders".
Company needs a fresh thoughts and new sales approach and i dont think it is possible with Budd.

AIHL requires further studies before any uptake I guess

There is little published high-quality evidence assessing Genedrive MT-RNR1 ID test. Only 1 study (1 full-text article and 1 corresponding conference abstract) was included in this briefing. The 1 relevant study is a prospective cohort study that compares the accuracy of the Genedrive MT-RNR1 ID test with existing targeted gene mutation testing, Sanger. The study does not explain the rationale for using Sanger over the other gene testing techniques such as pyrosequencing. However, the author confirms that Sanger sequencing was preferentially used because it is a faster test and is the gold standard test. The Genedrive MT-RNR1 ID System was initially validated against positive and negative patient samples that had been genotyped using pyrosequencing. The only outcome compared was accuracy. Further studies on its impact on clinical practice would be useful.

There is nothing in RNS, we are unable to sell any products because of no or very less demand for them…
Including AIHL which has moderate interests from UK

Big red day is coming…

Can’t believe Budd sold some tests.. would have been massive confidence boost if he could have mentioned the revenue.

I'm looking for
pottential poc orders/sales
Aihl uk rollout plan.
Update on EU AIHLpilot site and when does roll out commences
HCV status and future sales
Are we going be profitable soon?
Lets see what Budd got to say tomorrow. I have some predictions and so i sold out today.

I think most including myself are expecting some sales from covid POC to support the full roll out of AIHL. Which I very much doubt now.
That’s why I’m out this morning. I would buy back later if things are looking good for GDR
GLAH

As i expected Investors lack confidence in Budd
This is the same pattern happened last couple of years before presentation and nothing is going to change this year too unless Budd release good sales and revenue details.

The compnay certainly making money out the 6 machine and regular income from consumable.. may be not aweful lot at the moment to report. I need company to make their rollout plan clear and next 12 to 18 months income guidance from AIHL.

lol.. you show me a single RNS stating an order or sales since last results?

What are the chances of solid revenue to be made from covid POC, US DOD and AIHL in next 9 months to become profitable and continue operations without further raises next year?
The company needs to release some news about sales/revenue before presentation otherwise I'm out because i cant risk a big drop on 31st.

High risk share, if it comes out good it could easily 5 bag from the current levels

DB need to tell us about POC orders
DB need to atleast come out sand tell us the speed of AIHL roll out and sales from it. It is just the matter of Budd announce revenue/ sales this would fly past £1..

With out any of this why would you think this sp would move? Because the company has 9 months cash to survive.

The problem lies with teh company, they did not provide revenue details and did not say how long it would take to role out for rest of the UK and EU.
because we could only last 9 more months with money we got in bank.